Chambers SA, Allen E, Rahman A, Isenberg D. Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford). 2009;48:673–5.

Article  PubMed  Google Scholar 

Gomez A, Qiu V, Cederlund A, et al. Adverse health-related quality of life outcome despite adequate clinical response to treatment in systemic lupus erythematosus. Front Med. 2021;8: 651249.

Article  Google Scholar 

Lee YH, Choi S, Ji J, Song G. Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus. 2016;25:727–34.

Article  CAS  PubMed  Google Scholar 

Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther. 2015;17:183.

Article  PubMed  PubMed Central  Google Scholar 

Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–45.

Article  CAS  PubMed  Google Scholar 

Parra Sanchez AR, Voskuyl AE, van Vollenhoven RF. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation. Nat Rev Rheumatol. 2022;18:146–57.

Article  PubMed  Google Scholar 

van Vollenhoven RF, Bertsias G, Doria A, et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021;8: e000538.

Article  PubMed  PubMed Central  Google Scholar 

Golder V, Tsang-A-Sjoe M. Treatment targets in SLE: remission and low disease activity state. Rheumatology (Oxford). 2020;59:v19–28.

Article  CAS  PubMed  Google Scholar 

Gerosa M, Beretta L, Ramirez GA, et al. Long-term clinical outcome in systemic lupus erythematosus patients followed for more than 20 years: the Milan Systemic Lupus Erythematosus Consortium (SMiLE) cohort. J Clin Med. 2022;11:3587.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao D, Hao Y, Mu L, et al. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naive patients with systemic lupus erythematosus. Rheumatology (Oxford). 2020;59:3400–7.

Article  CAS  PubMed  Google Scholar 

Petri M, Magder LS. Comparison of remission and Lupus Low Disease Activity State in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheum. 2018;70:1790–5.

Article  Google Scholar 

Tani C, Vagelli R, Stagnaro C, Carli L, Mosca M. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med. 2018;5: e000234.

Article  PubMed  PubMed Central  Google Scholar 

Hao Y, Ji L, Gao D, et al. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study. Lupus Sci Med. 2022;9: e000553.

Article  PubMed  PubMed Central  Google Scholar 

Golder V, Kandane-Rathnayake R, Huq M, et al. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Lancet Rheumatol. 2019;1:E103–10.

Article  Google Scholar 

Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75:1615–21.

Article  CAS  PubMed  Google Scholar 

Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol. 2019;1:e95–102.

Article  Google Scholar 

Morand EF, Abreu G, Furie RA, Golder V, Tummala R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis [Internet]. 2023. https://doi.org/10.1136/ard-2022-222748. https://www.ncbi.nlm.nih.gov/pubmed/36690388.

Oon S, Huq M, Golder V, et al. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019;78:629–33.

Article  CAS  PubMed  Google Scholar 

Ramirez GA, Canti V, Moiola L, et al. Performance of SLE responder index and lupus low disease activity state in real life: a prospective cohort study. Int J Rheum Dis. 2019;22:1752–61.

Article  CAS  PubMed  Google Scholar 

Ugarte-Gil MF, Gamboa-Cardenas RV, Reátegui-Sokolova C, et al. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort. Lupus Sci Med. 2022;9: e000616.

Article  PubMed  PubMed Central  Google Scholar 

Kandane-Rathnayake R, Louthrenoo W, Hoi A, et al. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Res Ther. 2022;24:70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kandane-Rathnayake R, Golder V, Louthrenoo W, et al. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: a prospective, multinational, longitudinal cohort study. Lancet Rheumatol. 2022;4:e822–30.

Article  CAS  Google Scholar 

Sharma C, Raymond W, Eilertsen G, Nossent J. Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus. Arthritis Care Res. 2020;72:447–51.

Article  CAS  Google Scholar 

Merrill JT, van Vollenhoven RF, Buyon JP, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:332–40.

Article  CAS  PubMed  Google Scholar 

Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208–19.

Article  Google Scholar 

Morand EF, Trasieva T, Berglind A, Illei GG, Tummala R. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis. 2018;77:706–13.

Article  CAS  PubMed  Google Scholar 

Kalunian KC, Furie R, Morand EF, et al. A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheum. 2023;75:253–65.

Article  CAS  Google Scholar 

Morand EF, van Vollenhoven R, Furie R, et al. OP0051 Lupus Low disease activity state attainment in the phase 3 placebo-controlled TULIP long-term extension trial of anifrolumab. In: Oral presentation at: European Congress of Rheumatology (EULAR); 2023; Milan, Italy, 31 May–3 June 2023.

Morand E, Pike M, Merrill JT, et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2022;75:242–52.

Article  Google Scholar 

Morand EF, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020;59:2930–8.

Article  PubMed  Google Scholar 

Aranow C, Allaart C, Amoura Z, et al. Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: the phase 3, randomized, placebo-controlled BLISS-BELIEVE study. ACR convergence 2021; 2021; Virtual, 5–9 November.

Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet. 2023;401:1001–10.

Article  CAS  PubMed  Google Scholar 

van Vollenhoven R, Morand E, Furie R, et al. Attainment of remission with anifrolumab: a post hoc analysis of pooled TULIP-1 and TULIP-2 datasets. ACR Convergence 2022; 2022; Philadelphia, PA, 10–14 November.

Mackensen A, Müller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28:2124–32.

Article  CAS  PubMed  Google Scholar 

Emamikia S, Oon S, Gomez A, et al. Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2022;61:4752–62.

Article  PubMed  Google Scholar 

Golder V, Kandane-Rathnayake R, Hoi AY, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017;19:62.

Article  PubMed  PubMed Central  Google Scholar 

Golder V, Kandane-Rathnayake R, Li N, et al. Association of sustained Lupus Low Disease Activity State with improved outcomes in SLE: a multinational prospective cohort study. ACR Convergence 2022; 2022; Philadelphia, PA, 10–14 November.

Yeo AL, Koelmeyer R, Kandane-Rathnayake R, et al. Lupus low disease activity state and reduced direct health care costs in patients with systemic lupus erythematosus. Arthritis Care Res. 2020;72:1289–95.

Article  CAS  Google Scholar 

Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31.

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov. A single arm 24 weeks pilot study of belimumab in treatment of early systemic lupus erythematosus. 2022. https://clinicaltrials.gov/ct2/show/NCT04956484?term=belimumab&draw=2&rank=2. Accessed 22 Sept 2022.

ClinicalTrials.gov. Pilot trial of belimumab in early lupus. 2021. https://clinicaltrials.gov/ct2/show/NCT03543839?term=belimumab&draw=3&rank=22. Accessed 22 Sept 2022.

ClinicalTrials.gov. A study to evaluate effectiveness and safety of deucravacitinib (BMS-986165) compared with placebo in participants with active systemic lupus erythematosus (POETYK SLE-2). 2023. https://clinicaltrials.gov/ct2/show/NCT05620407?term=nct05620407&draw=2&rank=1. Accessed 15 Feb 2023.

ClinicalTrials.gov. Optimization of glucocorticoid taper strategies for SLE-ITP. 2022. https://clinicaltrials.gov/ct2/show/NCT05506033?term=NCT05506033&draw=2&rank=1. Accessed 26 Sept 2022.

Dougados M. Treat to target in axial spondyloarthritis: from its concept to its implementation. J Autoimmun. 2020;110: 102398.

Article  PubMed